Clinical Trials
12 trialsNCT05002816 2026-05-13
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Yale University
Phase 1/2 Active not recruiting
NCT05060627 2026-05-11
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
PETHEMA Foundation
Phase 1/2 Active not recruiting
NCT04126200 2026-05-06
DREAMM 5
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07084896 2026-05-06
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT02343042 2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Active not recruiting
NCT04246047 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06868654 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06868667 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT04822337 2026-04-16
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Active not recruiting
NCT04162210 2026-03-31
DREAMM-3
GlaxoSmithKline
Phase 3 Active not recruiting
NCT04876248 2026-03-31
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT04680468 2026-03-23
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
University of Pennsylvania
Phase 2 Active not recruiting